October 19, 2016
FDA approves Roche’s cancer immunotherapy Tecentriq for metastatic NSCLC
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 19, 2016
GW Pharmaceutical cancels trading shares on AIM on December 2, 1016, continues trading on NASDAQ
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
October 19, 2016
Advandec Oncotherapy’s Harley Street site planning permission granted
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.
October 19, 2016
Beximco Pharmaceutical to declare cash and stock dividends at next AGM
A Bangladesh based, AIM listed Beximco Pharmaceuticals has announced that it would declare/approve 5% final Cash Dividend, 5% Stock Dividend and 10% Cash Dividend
October 19, 2016
SuperSonic reports 10% revenue growth
SuperSonic Imagine has announced its sales for the third quarter to September 30, 2016.
October 19, 2016
Keopsys group makes changes in Quantel’s Board
KEOPSYS Group holding company, acquired for € 5 million, 93.8% of the capital of EURODYNE, which holds 1,184,513 QUANTEL shares and 1,928,579 voting rights, representing 14.6% of the capital and 21.3% of the voting rights of QUANTEL.
October 19, 2016
JNJ sales went up, net income $4,272M in Q3 2016
Johnson & Johnson has reported on Tuesday net earnings and diluted earnings per share for the third quarter of 2016 of$4.3 billion and $1.53, respectively. Third quarter 2015 net earnings included …
October 19, 2016
EMA’s CHMP reccomends Teva’s Trisenox indication extension
Teva Pharmaceutical has gotten a positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending an indication extension of Trisenox (arsenic trioxide).
October 19, 2016
Allergan releases its “lip pumping drug” to the US market
Allergan has announced that the latest addition to the Juvederm collection of fillers, Juvederm Volbella XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as “lipstick lines”, in adults over the age of 21.
October 19, 2016
Quantum Pharma names new CEO and makes other board changes
Quantum Pharma names new CEO and makes other board changes
@qp_group